LONDON (Alliance News) - Scancell Holdings PLC on Wednesday said its SCIB1 cancer drug is continuing to deliver "compelling" survival data during its phase 1/2 clinical trial in malignant melanoma.
Scancell, which develops immunotherapies for the treatment of cancer, said 19 of the 20 patients with resected tumours at study entry remain alive as of June 27. One patient who first experienced disease progression in September 2013 died in April this year, despite additional treatment with checkpoint inhibitors and radiation therapy.
Of the 16 patients who received 2-4 milligramme doses of SCIB1, only five patients have progressed and one has died, while only one new incidence of disease progression has been seen since November 2013.
Of the four patients who received 8mg doses of SCIB1, none have progressed and none have died.
Treatment for the eight patients in the long-term continued dosing phase was suspended last month after ongoing quality control analysis found the stored drug product no longer met the original specifications for the trial.
Scancell said on Tuesday it is manufacturing new SCIB1 material to support a new study of SCIB1 in combination with a checkpoint inhibitor for those eight patients. New material will be ready for use in nine to 12 months.
"SCIB1 continues to deliver compelling survival data in patients with resected Stage III/IV melanoma. It is particularly interesting to note that there has only been one new case of disease progression since November 2013 in the resected patients receiving 4mg doses of SCIB1, which gives us hope that SCIB1 might offer curative potential in this currently untreated patient group," Chief Executive Richard Goodfellow said in a statement.
Shares in Scancell were trading up 13% at 17.00 pence on Wednesday morning.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)